Sign InBreakout Stocks of Week 23 @ GER
NASDAQ was up last week (week 22) by 2.40% ending at 26,976.35 points after gaining 632.38 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are RWE Aktiengesellschaft GER:RWE. This stock has had a buy signal since May 29, 2026 when the price was 54.56€ , but have so far fallen 0% to 54.56€. Some other companies are on our watchlist to, among these are Deutsche Börse Aktiengesellschaft GER:DB1 Carl Zeiss Meditec AG GER:AFX BP p.l.c. GER:BPE5 and Nordex SE GER:NDX1 which all got a breakout pattern emerging.
| Date | Company | Price | Week 23 |
|---|---|---|---|
| Rwe Aktiengesellschaft | 54.56€ | 56.00€ | 2.64% |
| Deutsche Börse Aktiengesellschaft | 247.60€ | 245.90€ | -0.687% |
| Carl Zeiss Meditec Ag | 25.88€ | 26.74€ | 3.32% |
| Bp P.l.c. | 5.99€ | 6.27€ | 4.60% |
| Nordex Se | 41.40€ | 40.82€ | -1.40% |
The RWE Aktiengesellschaft stock price gained 0.147% on the last trading day (Friday, 29th May 2026), rising from 54.48€ to 54.56€. During the last trading day the stock fluctuated 1.36% from a day low at 54.28€ to a day high of 55.02€. The price has been going up and down for this period, and there has been a -1.16% loss for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 5 million more shares were traded than the day before. In total, 7 million shares were bought and sold for approximately 383.37€ million.
RWE Aktiengesellschaft holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About RWE Aktiengesellschaft:
RWE Aktiengesellschaft generates and supplies electricity from renewable and conventional sources primarily in Europe and the United States. It operates through five segments: Offshore Wind; Onshore Wind/Solar; Hydro/Biomass/Gas; Supply & Trading; and Coal/Nuclear. The company generates wind, solar, hydro, nuclear, gas, and biomass electricity. It also trades in energy commodities; and operates gas storage facilities, as well as battery storage activities. The company serves commercial, industrial, and corporate customers. RWE Aktiengesellschaft was founded in 1898 and is headquartered in Essen, Germany.
The Deutsche Börse Aktiengesellschaft stock price fell by -0.242% on the last day (Friday, 29th May 2026) from 248.20€ to 247.60€. It has now fallen 4 days in a row. During the last trading day the stock fluctuated 1.63% from a day low at 245.40€ to a day high of 249.40€. The price has fallen in 6 of the last 10 days but is still up by 1.31% over the past 2 weeks. Volume has increased on the last day by 489 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 838 thousand shares were bought and sold for approximately 207.38€ million.
Deutsche Börse Aktiengesellschaft holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Deutsche Börse Aktiengesellschaft:
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
The Carl Zeiss Meditec AG stock price fell by -2.19% on the last day (Friday, 29th May 2026) from 26.46€ to 25.88€. During the last trading day the stock fluctuated 4.46% from a day low at 25.54€ to a day high of 26.68€. The price has risen in 6 of the last 10 days and is up by 4.02% over the past 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -54 thousand shares and in total, 202 thousand shares were bought and sold for approximately 5.24€ million.
Carl Zeiss Meditec AG holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Carl Zeiss Meditec AG:
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers products and solutions for the diagnosis and treatment of eye diseases; and systems and consumables for cataract, retinal, and refractive surgeries. It serves practicing ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The Microsurgery segment offers visualization solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, dental and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
The BP p.l.c. stock price gained 0.99% on the last trading day (Friday, 29th May 2026), rising from 5.94€ to 5.99€. During the last trading day the stock fluctuated 1.83% from a day low at 5.90€ to a day high of 6.01€. The price has fallen in 7 of the last 10 days and is down by -5.32% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 873 more shares were traded than the day before. In total, 2 million shares were bought and sold for approximately 9.33€ million.
The BP p.l.c. stock holds several negative signals and despite the positive trend, we believe BP p.l.c. will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
About BP p.l.c.:
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
The Nordex SE stock price fell by -1.00% on the last day (Friday, 29th May 2026) from 41.82€ to 41.40€. During the last trading day the stock fluctuated 2.68% from a day low at 41.06€ to a day high of 42.16€. The price has fallen in 6 of the last 10 days and is down by -8.57% for this period. Volume has increased on the last day by 257 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 776 thousand shares were bought and sold for approximately 32.14€ million.
The Nordex SE stock holds several negative signals and despite the positive trend, we believe Nordex SE will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.
About Nordex SE:
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
IDYA
$28.84
|
4.82% | Jun 11 |
EAT
$140.46
|
11.23% | Jun 05 |
TPR
$140.47
|
7.49% | Jun 04 |
LITE
$905.00
|
5.77% | Jun 01 |
|
W
WCLD
$27.34
|
12.84% | Apr 29 |
